echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The market value fell by $600 million Chronic Cough BLU-5937 concept verification fell as expected.

    The market value fell by $600 million Chronic Cough BLU-5937 concept verification fell as expected.

    • Last Update: 2020-07-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On July 06, 2020, BELLUS Health announced relief data from a clinical trial of the conceptual validation of P2X3 receptor blockers, and the safety advantages of BLU-5937 have been seen, but the clinical benefits are not as expected, and in patients with relapsed chronic coughs, BLU-5937 vsplacebosThe frequency of coughs decreased by 17%, clinical endpoints, unexpected failures, the market value of the company dropped by $600 millionprevious articles have presented several points of view: 1Chronic cough has a huge unmet clinical need, P2X3 has been a confirmed target for chronic cough; 2Gefapixant has been the first to complete two phase 3 critical clinical trials; COUGH-1/2 top line data show that gefapixant 45mg reaches the clinical primary endpoint; 3First-in-class drug gefapixant due to poor selectivity, taste disorder is a common concern; The article mentions BLU-5937, whose first proof-of-concept clinical trial RELIEF is highly anticipated because of its highly selective and potentially safe advantages for P2X3RELIEF data is heavy, lower than expected, unexpected failure BLU-5937 RELIEF (NCT03979638) clinical trial designITT population, BLU-5937 failed to significantly reduce the number of coughs in patientssevere cough patients, BLU-5937 can significantly reduce the frequency of coughing patients such an unexpected failure, BELLUS Health always have to find a way to continue, at present, BELLUS Health offers 2 things to hope for: First, the old-fashioned way to identify subgroups with significant clinical benefits, data show that BLU-5937 can significantly reduce the cough frequency of patients with severe cough, BLU-5937 vsplacebo, cough frequency decreased by 32%, so-called severe cough is an hourly (median) cough number of 32BLU-5937 can significantly reduce the cough frequency of patients with severe coughthe clinical benefits of BLU-5937 increased with the severity of coughsecond hope: the proportion of attention-raising taste abnormality is indeed low, BLU-5937 is about 5-10%BLU-5937 caused by the taste abnormality of the same type of leastThe next step for the BLU-5937 is from bellUS Health's late pipeline, the BLU-5937 is one of the most important, and the company certainly can't give up easilyTo sum up, 1 Blu-5937 is also very low in patients with taste abnormalities due to its extremely high P2X3 receptor selectivity; Blu-5937 has the highest share of hP2X3 receptors compared to gefapixant and S-600918, but BELLUS Health noted on a conference call that the higher the drug's affinity to P2X3 receptors, the worse the clinical benefits of the drug may be; This subgroup analysis showed significant clinical benefits of the drug in patients with severe cough Blu-5937 in the same drug, relatively, clinical benefits are not high based on this, BLU-5937 will next have an important action: 1 In the fourth quarter of 2020, BLU-5937 will conduct a 2b clinical trial in patients with severe cough to regain confidence; The company expects the two clinical trials to cost $20 million and $10 million, respectively So far, 1 Mercadon gefapixant remains the leading drug of its kind, and subsequently expects it to disclose more detailed clinical trial data, particularly drug safety data; Blu-5937 is expected to initiate new clinical trials and further confirm the clinical benefits of the drug in patients with severe coughs This article no longer covers diseases, targets and potential market introductions, please refer to the author of the previous
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.